# Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

> **NCT07231575** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 39 (estimated)

## Conditions studied

- Neoadjuvant Immunotherapy
- NSCLC
- Chemo-free Therapy

## Interventions

- **RADIATION:** SBRT
- **DRUG:** Immunotherapy
- **DRUG:** antiangiogenesis therapy

## Key facts

- **NCT ID:** NCT07231575
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-10
- **Primary completion:** 2027-11-30
- **Final completion:** 2032-05-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07231575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07231575, "Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07231575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*